SuperworthOrthopediatrics EPS KIDS
Diluted earnings per share by quarter and over the last twelve months, from 2016.
- Last 12 months, to Jun 30, 2026
- −$1.68
- Latest quarter, Q2 FY26
- −$0.30
- Fiscal year 2025
- −$1.69
Orthopediatrics' earnings per share was −$1.68 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.30.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.69 | n/a |
| FY2024 | −$1.63 | n/a |
| FY2023 | −$0.92 | −9300% |
| FY2022 | $0.01 | n/a |
| FY2021 | −$0.84 | n/a |
| FY2020 | −$1.81 | n/a |
| FY2019 | −$0.93 | n/a |
| FY2018 | −$0.96 | n/a |
| FY2017 | −$6.22 | n/a |
| FY2016 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.30 | n/a | −$1.68 | |
| Q1 FY26 | −$0.45 | n/a | −$1.68 | |
| Q4 FY25 | −$0.43 | n/a | −$1.69 | |
| Q3 FY25 | −$0.50 | n/a | −$1.95 | |
| Q2 FY25 | −$0.30 | n/a | −$1.79 | |
| Q1 FY25 | −$0.46 | n/a | −$1.75 | |
| Q4 FY24 | −$0.69 | n/a | −$1.63 | |
| Q3 FY24 | −$0.34 | n/a | −$1.23 | |
| Q2 FY24 | −$0.26 | n/a | −$1.09 | |
| Q1 FY24 | −$0.34 | n/a | −$0.96 | |
| Q4 FY23 | −$0.29 | n/a | −$0.92 | |
| Q3 FY23 | −$0.20 | −123% | −$1.00 |
Against its peers
Companies in Medical - Instruments & Supplies nearest Orthopediatrics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| KIDSOrthopediatrics | −$1.68 | |
| MOVMovado | $1.80 | +137% a year |
| MDXGMimedx | $0.04 | −81% a year |
| TCMDTactile Systems Technology | $1.08 | +74% a year |
| EMBCEmbecta | $1.47 | +3% a year |
| IRMDIradimed | $1.79 | +10% a year |
| STAAStaar Surgical | $0.07 | |
| BVSBioventus | $0.77 | |
| CDRECadre | $0.81 | −14% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| EYENational Vision | $0.61 | |
| Peer median | $0.79 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Orthopediatrics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.